Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial

Annals of Internal Medicine

Volumn 130, Issue 6, 1999, Pages 478-486

  Moreland, Larry W ^b   Schiff, Michael H ^b   Baumgartner, Scott W ^b   Tindall, Elizabeth A ^b   Fleischmann, Roy M ^b   Bulpitt, Ken J ^b   Weaver, Arthur L ^b   Keystone, Edward C ^b   Furst, Daniel E ^b   Mease, Philip J ^b   Ruderman, Eric M ^b   Horwitz, David A ^b   Arkfeld, Daniel G ^b   Garrison, Leslie ^b   Burge, Daniel J ^b   Blosch, Consuelo M ^b   Lange, Mary L M ^b   McDonnell, Neil D ^b   Weinblatt, Michael E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ANTIHISTAMINIC AGENT; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; ETANERCEPT; FC RECEPTOR; HYBRID PROTEIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0033574147     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-6-199903160-00004     Document Type: Article

References (37)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322:1277-89.
2. Hazes JM, Silman AJ. Review of UK data on the rheumatic diseases - 2. Rheumatoid arthritis. Br J Rheumatol. 1990;29:310-2.
3. Mitchell JM, Burkhauser RV, Pincus T. The importance of age, education, and comorbidity in the substantial earnings losses of individuals with symmet-ric polyarthritis. Arthritis Rheum. 1988;31:348-57.
4. Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol. 1984;11: 158-61.
5. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 1996;39:616-22.
6. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med. 1994;330:1368-75.
7. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986;322:547-9.
8. von Asmuth EJ, van der Linden CJ, Leeuwenberg JF, Buurman WA. Involvement of the CD11b/CD18 integrin, but not of the endothelial cell adhesion molecules ELAM-1 and ICAM-1 in tumor necrosis factor-alpha-induced neutrophil toxicity. J Immunol. 1991;147:3869-75.
9. Thornton SC, Por SB, Penny R, Richter M, Shelley L, Breit SN. Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumour necrosis factor-alpha. Clin Exp Immunol. 1991;86:79-86.
10. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Mature. 1986;319:516-8.
11. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985;162:2163-8.
12. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989;264: 11974-80.
13. Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A, et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol. 1989;42:270-5.
14. Schutze S, Scheurich P, Pfizenmaier K, Kronke M. Tumor necrosis factor signal transduction. Tissue-specific serine phosphorylation of a 26-kDa cytosolic protein. J Biol Chem. 1989;264:3562-7.
15. Robaye B, Hepburn A, Lecocq R, Fiers W, Boeynaems JM, Dumont JE. Tumor necrosis factor-alpha induces the phosphorylation of 28kDa stress proteins in endothelial cells: possible role in protection against cytotoxicity? Biochem Biophys Res Commun. 1989;163:301-8.
16. Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 1990;248:1019-23.
17. Jones EY, Stuart DI, Walker NP. Structure of tumour necrosis factor. Mature. 1989;338:225-8.
18. Dower SK, Smith CA, Park LS. Human cytokine receptors. J Clin Immunol. 1990;10:289-99.
19. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleishcmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-7.
20. Moreland LW, Margolies G, Heck LW Jr, Saway A, Blosch C, Hanna R, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol. 1996;23:1849-55.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
22. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35: 498-502.
23. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9:789-93.
24. Fries JF, Singh G, Ramey DR. Stanford RA, January 1996, Phase 30. Palo Alto, CA: Stanford Univ: 1996.
25. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-35.
26. Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum. 1990;33:477-84.
27. Stuart AA. A test for homogeneity of the marginal distributions in a two-way classification. Biometrica. 1955;42:412-6.
28. Wilke W, Cash JM. The use of slower-acting (class III) symptom-modifying antirheumatic drugs in rheumatoid arthritis. Clinical Immunotherapy. 1996;5: 309-25.
29. Elkayam O, Yaron M, Zhukovsky G, Segal R, Caspi D. Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients. Rheumatol Int. 1997; 17:49-53.
30. Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis. 1996;55:187-9.
31. Kremer JM, Alarcon GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37:316-28.
32. Bendix G, Bjelle A. A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 1996;55:169-76.
33. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-9.
34. Moreland LW, Baumgartner SW, Tindall EA, Schiff MH, Flieschmann RM, Weaver AL, et al. Longterm safety and efficacy of TNF receptor (p75) fusion protein (TNFR:Fc; Enbrel™) in DMARD refractory rheumatoid arthritis (RA) [Abstract]. Arthritis Rheum. 1998;41(Suppl):S364.
35. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994;344:1125-7.
36. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Somolen JS, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-10.
37. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36:1681-90.